Lexeo Therapeutics达成研究合作 探索AAV基因疗法靶向心脏递送新路径

美股速递
Jan 08

基因治疗公司Lexeo Therapeutics日前宣布启动一项前沿研究合作项目,旨在探索腺相关病毒载体基因疗法在心脏靶向递送领域的创新应用。该合作将聚焦于优化基因治疗载体对心肌组织的特异性靶向能力,为心血管疾病治疗开辟潜在的新途径。

通过整合多方科研资源与技术专长,研究团队计划开发新一代精准递送系统,以期提升基因疗法在心脏疾病治疗中的安全性与有效性。这项突破性探索有望为遗传性心肌病等难治性心血管疾病带来颠覆性的治疗解决方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10